scholarly journals Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: Results on local control and survival

2011 ◽  
Vol 100 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Enja J. Bantema-Joppe ◽  
Hans Paul van der Laan ◽  
Geertruida H. de Bock ◽  
Robin Wijsman ◽  
Wil V. Dolsma ◽  
...  
Keyword(s):  
Local Control ◽  
Three Dimensional ◽  
Breast Conserving Therapy ◽  
Simultaneous Integrated Boost ◽  
Integrated Boost

scholarly journals Comparison of Simultaneous Integrated Boost and Late-course Boost Intensity-modulated Radiation Therapy in the Treatment of Esophageal Carcinoma

2021 ◽  
Author(s):  
Yu Xiao ◽  
Guobo Du ◽  
Jianping Hu ◽  
Tingting Wu ◽  
Xue Meng ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Esophageal Carcinoma ◽  
Local Control ◽  
Intensity Modulated Radiation Therapy ◽  
Simultaneous Integrated Boost ◽  
Entire Group ◽  
Target Area ◽  
Intensity Modulated ◽  
Integrated Boost

Abstract This paper aimed to analyze and compare the outcomes of esophageal carcinoma treated with simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) and late-course boost intensity-modulated radiation therapy (LCB-IMRT). The retrospective study was designed to analyze the clinical data of 274 esophageal cancer patients who received radical radiotherapy in the Oncology Department of our hospital, from January 2014 to December 2017. Propensity score matching analysis was used to balance the variable differences in the two groups. Survival, toxicities, and target dose were observed and compared between the two groups. Statistical analysis was performed using SPSS 24.0 software. P<0.05 judged to be statistically significant. 200 patients were finally included after propensity scores matching , The 1-, 3-, and 5-year overall survival and local control rates of the entire group were 80.5% vs. 67.6%, 38.2% vs. 31.3%，and 22.2% vs. 20.4%, respectively. The 1-, 3-, and 5-year overall survival rates of the SIB-IMRT and LCB-IMRT group were 85.0% vs. 76.0%, 41.8% vs. 34.5%, and 25.5% vs. 21.3%, respectively (P＞0.05). The 1-, 3-, and 5- year local control rates of the SIB-IMRT and LCB-IMRT group were 77.3% vs. 58.0%, 31.4% vs. 30.1%, and 20.0% vs. 20.7%, respectively (P＞0.05). The recent total effective rates of the SIB-IMRT and LCB-IMRT group were 96.0% vs. 92.0% (P＞0.05). There were statistically significant differences in the incidence of ≥2 grade acute radiation esophagitis and pneumonia between the two groups (P＜0.05). The does of lung V5, lung V10, lung Dmean, and spinal cord Dmax in the SIB-IMRT group were significantly lower than those in LCB-IMRT group (P＜0.05). Patients age, tumor location, tumor length, gross tumor target volume, N stage were independent prognostic factors of overall survival and local control. Compared with the LCB-IMRT group, the survival prognosis of the SIB-IMRT group has benefit trend, patients in the SIB-IMRT group received less radiation dose to the normal organs around the target area, and the toxicities effects of radiotherapy were lighter, which is more conducive to the protection of normal tissues around the target area.

Effect of intensity-modulated radiation therapy with SIB technique on local control and toxicity for neoadjuvant pelvic radiation with concurrent 5-fluorouracil based chemotherapy for rectal cancer compared with three-dimensional conformal radiation therapies.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 632-632
Author(s):  
Nitika Thawani ◽  
Vyas Shilpa ◽  
Shaakir Hasan ◽  
Gabriel Axelrud ◽  
Deb Niloyjyoti ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Radiation Therapy ◽  
Local Control ◽  
Intensity Modulated Radiation Therapy ◽  
Simultaneous Integrated Boost ◽  
P Value ◽  
Hematologic Toxicity ◽  
Pelvic Radiation ◽  
Intensity Modulated ◽  
Integrated Boost

632 Background: To compare the areas of residual disease after neoadjuvant pelvic radiation with 5-FU based chemotherapy for rectal cancer using Intensity Modulated Radiation Therapy (IMRT) with simultaneous integrated boost (SIB) technique compared to 3D Conformal Radiation Therapy (3DCRT) Methods: Fourty nine (49) consecutive rectal cancer patients treated with pelvic radiation and concurrent 5-FU based chemotherapy were analyzed. We compared twenty-eight (28) patients treated on an institutional IMRT protocol versus twenty-one (21) patients treated with 3DCRT. All patients received 45-50.4 Gy to the pelvis in 3DCRT group. All patients with IMRT received 45 Gy in 25 fractions to the pelvic no des. The primary rectal tumor recieved a simultaneous integrated boost to a dose of 50 Gy in 25 fractions. IMRT planning was done with dose constraints for bladder, rectum, and small bowel and bone marrow. All patients in both groups received 5-FU based chemotherapy during radiation. Evaluation of toxicity was based on RTOG criteria. 2 patients in the 3DCRT group and 2 in IMRT group received either growth factors or blood-products transfusion and needed hospitalization during treatment secondary to acute toxicities. Results: All patients completed their prescribed course of radiation. CR rates were 5/21(23%) in 3DCRT and 4/28(25%) in the IMRT-SIB (p-value 0.74). 9/21(42%) in 3D and 19/29(65%) in the IMRT group underwent Low anterior resection according to the location of the tumor. There was no grade 4 toxicity in the IMRT-SIB group. Overall grade 2 toxicity in 3D Vs IMRT-SIB group was - GI -52% Vs 19%, GU- 8% Vs 8%, skin 42 Vs 4%, hematologic 33 Vs 47%. Overall Grade 1 toxicity in 3DCRT Vs IMRT group was- GI- 33% Vs 52%, GU 23% vs 28%, Skin 52% Vs 38%, hematologic 4% Vs 33%. Conclusions: Neoadjuvant pelvic radiation with 5 FU for rectal cancer has similar local control rates. There is less GI, skin and hematologic toxicity when delivered via IMRT-SIB versus 3DCRT. IMRT is safe and may allow dose escalation with potential probability of increased tumor response.

Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 537-537
Author(s):  
B. Engels ◽  
K. Tournel ◽  
H. Everaert ◽  
A. Sermeus ◽  
G. Storme ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Local Control ◽  
Helical Tomotherapy ◽  
Combined Treatment ◽  
Progression Free Survival ◽  
Simultaneous Integrated Boost ◽  
Concomitant Chemotherapy ◽  
Image Guided Radiotherapy ◽  
Integrated Boost ◽  
Grade 3

537 Background: The addition of concomitant chemotherapy to preoperative radiotherapy is standard of care for patients with T3-4 rectal cancer. The combined treatment modality increases the complete response rate and local control, but has no impact on survival or the incidence of distant metastases. Besides, it is associated with considerable toxicity. As an alternative strategy, we explored prospectively preoperative helical tomotherapy with a simultaneous integrated boost (SIB). Methods: 106 patients were treated with intensity-modulated and image-guided radiotherapy using the Tomotherapy Hi-Art II system. A dose of 46 Gy, in daily fractions of 2 Gy, was delivered to the mesorectum and draining lymph nodes, without concomitant chemotherapy. In patients with a circumferential resection margin (CRM) less than 2 mm on magnetic resonance imaging, a SIB was delivered to the tumor up to a total dose of 55.2 Gy. Acute and late side effects were scored using the NCI-CTC AE v. 3.0. Stage III patients received standard adjuvant chemotherapy. Results: 100 patients (94%) presented with a T3-4 tumor, of which 52 patients entered the boost group (CRM < 2 mm). 54 patients entered the no-boost group. One patient in the no-boost group developed a radiohypersensitivity reaction, resulting in a complete tumor remission, a grade 3 acute and grade 5 late enteritis. No other grade 3+ acute toxicities occurred. With a median follow-up of 32 months (range, 6-58), grade 3+ late gastrointestinal and urinary toxicity was observed in 7 patients (6%) and 4 patients (4%), respectively. Until yet, 2 locoregional relapses were observed. The actuarial 3-year local control, progression-free survival, and overall survival were 97%, 74% and 83%, respectively. Conclusions: Preoperative helical tomotherapy displays a favourable toxicity profile in patients with T3-4 rectal cancer. A SIB can be safely administered in patients with a narrow CRM and results in a promising local control. No significant financial relationships to disclose.

Five year outcomes of hypofractionated simultaneous integrated boost irradiation in breast conserving therapy; patterns of recurrence

2013 ◽  
Vol 108 (2) ◽  
pp. 269-272 ◽  
Author(s):  
Enja J. Bantema-Joppe ◽  
Eline J. Vredeveld ◽  
Geertruida H. de Bock ◽  
Dianne M. Busz ◽  
Marleen Woltman-van Iersel ◽  
...  
Keyword(s):  
Breast Conserving Therapy ◽  
Simultaneous Integrated Boost ◽  
Boost Irradiation ◽  
Integrated Boost ◽  
Patterns Of Recurrence

scholarly journals Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results

2016 ◽  
Vol 16 (3) ◽  
pp. 310-315 ◽  
Author(s):  
Rosario Mazzola ◽  
Francesco Ricchetti ◽  
Alba Fiorentino ◽  
Niccolò Giaj Levra ◽  
Sergio Fersino ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Overall Survival ◽  
Elderly Patients ◽  
Local Control ◽  
Volumetric Modulated Arc Therapy ◽  
Simultaneous Integrated Boost ◽  
Advanced Cervical Cancer ◽  
Arc Therapy ◽  
Integrated Boost ◽  
Weekly Cisplatin

Background: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. Materials and Methods: Inclusion criteria of this prospective study were age ≥70 years, Karnofsky performance status 70 to 100, locally advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was 40 mg/mq. Results: A total of 30 patients were recruited. Median follow-up was 32 months (range: 8-48 months). Median age was 72 years (range: 70-84 years). The 3-year overall survival and local control were 93% and 80%, respectively. The median time to progression was 24 months (range: 6-30 months). Analyzing clinical outcome grouping based on the stage of disease, II versus III, the 3-year overall survival was 100% and 85%, respectively. The 3-year local control was 91% for stage II and 67% for stage III. Acute and late toxicities were acceptable without severe events. Conclusion: Weekly cisplatin and volumetric-modulated arc therapy–simultaneous integrated boost for radical treatment of advanced cervical cancer in the current cohort of elderly patients were feasible. Long-term results and prospective randomized trials are advocated.

Sign in / Sign up

Export Citation Format

Share Document